Covered recipient · General Payments record
ERIC RYAN PENTON
Allopathic & Osteopathic Physicians General Practice
General Payments · PY2023–2024
$463.68
- Reported across 25 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $297.10 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $59.24 | 3 |
| Acerta Pharma LLC | $43.05 | 3 |
| Exact Sciences Corporation | $40.34 | 2 |
| PFIZER INC. | $29.38 | 2 |
| DEXCOM, INC. | $26.38 | 1 |
| Radius Health, Inc. | $23.51 | 1 |
| Amgen Inc. | $19.82 | 1 |
| Lilly USA, LLC | $19.73 | 1 |
| Novo Nordisk AS | $19.41 | 1 |
| Otsuka America Pharmaceutical, Inc. | $16.24 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $15.33 | 04/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105234453 | CMS |
| ABBVIE INC. | $13.35 | 07/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105234457 | CMS |
| ABBVIE INC. | $30.56 | 08/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105234461 | CMS |
| Amgen Inc. | $19.82 | 08/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117351131 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.41 | 08/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104586762 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.34 | 08/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105852410 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.30 | 11/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105496709 | CMS |
| Dexcom, Inc. | $26.38 | 09/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153299237 | CMS |
| Exact Sciences Corporation | $18.74 | 04/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114552498 | CMS |
| Exact Sciences Corporation | $21.60 | 11/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114552502 | CMS |
| Lilly USA, LLC | $19.73 | 09/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134967785 | CMS |
| Novo Nordisk Inc | $19.41 | 06/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096660100 | CMS |
| Otsuka America Pharmaceutical, Inc. | $16.24 | 09/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118959973 | CMS |
| PFIZER INC. | $13.83 | 05/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131605741 | CMS |
| PFIZER INC. | $15.55 | 10/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132110287 | CMS |
| Radius Health, Inc. | $23.51 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089950660 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2023, 2024
- Source files
- Dataset page · Bulk file · PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.